Seeking Alpha
24 Oct 2026, 04:20 UTC · 4h ago
U.S. IPO Weekly Recap: Trickle Of Biotech Activity Continues Amid Tech Sell-Off
Impact · against what's priced in
The successful pricing of Lycia Therapeutics' IPO at the top of its range provides a positive initial signal for the stock. However, the broader market faces immediate selling pressure from six upcoming IPO lock-up expirations.
- LYCA+0.40
No priced-in read yet
- In context
The company priced its IPO at the top of its range and successfully upsized the offering, indicating strong initial investor demand.
Read from the article alone
Top 3 movers · tap to explore
